The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 1.48 (26.812%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 6.20
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 21st Oct 2014 08:50

African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating.Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy recommendation.Antofagasta: JP Morgan reduces target price from 830p to 760p maintaining a neutral rating.BHP Billiton: JP Morgan reduces target price from 2250p to 2180p keeping a neutral rating.Brooks Macdonald: Numis reduces target price from 1550p to 1470p retaining its hold recommendation.Brown (N) Group: Credit Suisse reduces target price from 518p to 330p downgrading to neutral.BT Group: Goldman Sachs cuts target price from 620p to 600p retaining a strong buy recommendation.Cable & Wireless Communications: JP Morgan lowers target price from 53p to 50p and maintains a neutral rating.Dairy Crest: UBS cuts target price from 460p to 410p retaining a neutral rating.Devro: N+1 Singer upgrades from hold to buy with a target price of 257p.Dialight: Investec upgrades from sell to hold with a target price of 850p.GKN: JP Morgan reduces target price from 460p to 370p reiterating its overweight rating.Go Ahead Group: Investec increases target price from 2670p to 2750p and leaves its buy recommendation unchanged.Hellermann Tyton: UBS initiates with a target price of 300p and a neutral rating.Hochschild Mining: JP Morgan cuts target price from 185p to 150p keeping its neutral rating.Informa: Westhouse Securities upgrades from neutral to buy with a target price of 554p.Inmarsat: JP Morgan ups target price from 810p to 840p and reiterates an overweight rating.Kazakhmys: JP Morgan cuts target price from 400p to 375p and stays with its overweight rating.Lloyds Banking Group: Credit Suisse shifts target price from 68p to 72p and stays with its neutral rating.NMC Health: Investec initiates with a target price of 610p and a buy recommendation.Petropavlovsk: JP Morgan lowers target price from 20p to 10p and reiterates an underweight rating.President Energy: Canaccord Genuity moves target price from 50p to 60p and retains its speculative buy recommendation.Redefine: Deutsche Bank lowers target price from 56p to 53p keeping its hold recommendation.Rightmove: Credit Suisse reduces target price from 3100p to 2655p and reiterates an outperform rating.Standard Chartered: Credit Suisse reduces target price from 1150p to 1020p and maintains an underperform rating.Synairgen: N+1 Singer initiates with a target price of 49p and a buy recommendation.Talk Talk Telecom: Goldman Sachs cuts target price from 450p to 435p and maintains a buy recommendation.Telecity Group: JP Morgan ups target price from 900p to 925p and keeps an overweight rating.Travis Perkins: UBS reduces target price from 2100p to 2000p reiterating a buy recommendation. Deutsche Bank lowers target price from 1901p to 1898p and keeps its hold recommendation.Vedanta Resources: JP Morgan reduces target price from 1130p to 1030p and retains a neutral rating.William Hill: Canaccord Genuity moves target price from 350p to 365p and keeps a hold recommendation.Zoopla Property: Credit Suisse cuts target price from 290p to 270p leaving its outperform rating unaltered.
More News
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
26 May 2020 13:55

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more
29 Mar 2020 21:00

Sunday share tips: Synairgen, Hollywood Bowl

(Sharecast News) - The Sunday Times's Sabah Meddings recommends buying shares of Synairgen arguing that the Covid-19 pandemic may have given the firm a new lease on life.

Read more
29 Mar 2020 20:57

Sunday newspaper round-up: Restrictions, Unemployment, Blood plasma

(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times

Read more
26 Mar 2020 14:26

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

Read more
26 Mar 2020 06:58

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Read more
18 Mar 2020 18:42

Britain's Synairgen gets green light for coronavirus drug trial

By Paul SandleLONDON, March 18 (Reuters) - British pharmaceutical company Synairgen said on Wednesday it had the go-ahead to test a drug that could boost the lung function of patients with coronavirus, potentially assisting in the global fight aga...

Read more
18 Mar 2020 16:59

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Read more
18 Mar 2020 11:17

Synairgen to begin trial of potential Covid-19 therapy

(Sharecast News) - Respiratory drug discovery company Synairgen has received expedited approvals from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of 'SNG001', an inhaled formulation of interferon-beta-1a, in Covid-19 coronavirus patients, to potentially assist with the global virus pandemic.

Read more
1 Oct 2019 13:42

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Read more
27 Sep 2019 13:32

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Read more
24 Jul 2019 12:58

Synairgen Encouraged By Findings So Far In Interferon Beta COPD Study

(Alliance News) - Synairgen PLC on Wednesday said a phase two trial in its inhaled interferon beta programme has found cold and flu infections worsen symptoms for chronic obstructive pulmonary in

Read more
9 Jul 2019 09:26

CORRECT (Jul 8): Woodford Transfers Company Stakes After Omnis Departs

(Correcting that Woodford Investment Management transferred a number of stakes following Omnis's decision. It did not sell these stakes, as was originally reported.)(Alliance News) - of

Read more
18 Apr 2019 11:52

Synairgen Non-Executive Director Paul Clegg To Retire In June

LONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June Buchanan,

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.